Launch of FIRMAGON® (degarelix), a GnRH blocker for advanced hormone-dependent prostate cancer.

Ferring Headquarters and new production facility open in Saint-Prex, Switzerland. The facility provides additional production capacity for Ferring’s dry products…

Ferring breaks the ground for the building of its new state-of-the-art multi-purpose site in Saint-Prex, Switzerland and thereby continues its…

On January 1st the new Ferring International Center building in Ørestad, Copenhagen opened for business. With its 20 floors, designed…

In 2000, Ferring launched its latest medicine, TRACTOCILE® (atosiban), a new chemical entity developed by Ferring’s researchers for the treatment…

Dr. Frederik Paulsen, Ferring’s founder, died at the age of 88, after having spent his last 17 years on his…

Ferring launched ZOMACTON® (hGH) for the treatment of growth hormone deficiency (GHD) in children and for the treatment of girls…

Ferring became the main sponsor of the ESPE (European Society for Paediatric Endocrinology) Winter School for young paediatric endocrinologists from…

In June of this year Ferring launched its first product in the area of infertility, MENOGON® (menotropin) for the treatment…

Ferring BV entered into a joint-venture with Léciva a.s., the largest pharmaceutical company in the Czech Republic at that time.